Medicamen Biotech Limited — Results, 12-08-2025: Integrated Filing- Financial

Medicamen Biotech Q1 FY25 Results Snapshot:

**Revenue Performance:** The company reported consolidated revenue of Rs 102.37 Cr for Q1 FY25, a modest 2.66% year-over-year increase from Rs 99.72 Cr in Q1 FY24.

**Profitability and EPS:** Consolidated net profit surged 9.44% YoY to Rs 12.06 Cr in Q1 FY25, up from Rs 11.02 Cr. This led to an improved EPS of Rs 12.72, compared to Rs 11.63 in the prior year. The better profit growth signals improved operational efficiency.

**Operational Costs:** Total expenses increased slightly to Rs 86.19 Cr. While material and employee costs saw minor increases, a slight reduction in finance and other expenses contributed positively to the bottom line, reflecting prudent cost management.

**Key Metrics:** The Board has proposed a final dividend of Re. 1 per equity share (10%) for FY24-25, subject to shareholder approval at the upcoming AGM.

**Management Commentary / Strategic Outlook:** The board has strengthened its leadership, appointing Mr. Ashwani Kumar Sharma as a Whole-time Director (Executive Director) to leverage his supply chain expertise. Additionally, Mr. Sham Goel (finance) and Mr. Shaival Saurabh (branding) have joined as Independent Directors, bringing diverse experience to the board.

**Final Takeaway:** Medicamen Biotech shows stable top-line growth with healthier profit expansion, suggesting effective cost controls. The new board appointments and dividend proposal are positive indicators for investors.